Key Highlights
- John Liles, Ph.D., appointed as VP Biology and Translational Science at Moonwalk Biosciences.
- Formation of a world-class Cardiometabolic Advisory Board.
- Dr. Liles brings 17+ years of drug discovery experience, including roles at Chinook Therapeutics and Gilead Sciences.
- Moonwalk’s advisory board includes experts from Rockefeller University, UMass Chan Medical School, and Harvard Medical School.
Source: Business Wire
Notable Quotes
- “We are thrilled to welcome John to our team and announce the formation of our cardiometabolic advisory board. John’s expertise in translating innovative therapeutics from discovery through IND will accelerate our ambitious R&D efforts.” — Alex Aravanis, M.D., Ph.D., Co-founder & CEO at Moonwalk Biosciences
- “I’m excited to join the Moonwalk team at a pivotal time as the company advances its preclinical efforts to pioneer new insights about epigenetic biology and engineering cell state.” — John Liles, Ph.D., VP Biology and Translational Science at Moonwalk Biosciences
SoHC's Take
Moonwalk Biosciences’ strategic appointment of Dr. John Liles, alongside the formation of a distinguished Cardiometabolic Advisory Board, underscores the company’s commitment to advancing the frontier of epigenetic biology and AI-driven therapeutic discovery. Dr. Liles’ extensive experience in drug discovery, particularly in the areas of liver, kidney, lung, and cardiovascular diseases, will likely accelerate Moonwalk’s research and development efforts. The advisory board, comprised of leading experts from prestigious institutions, further strengthens Moonwalk’s potential to address significant unmet needs in cardiometabolic disease through innovative epigenetic approaches.
